WO1996003142A1 - Drug delivery composition for the nasal administration of antiviral agents - Google Patents
Drug delivery composition for the nasal administration of antiviral agents Download PDFInfo
- Publication number
- WO1996003142A1 WO1996003142A1 PCT/GB1995/001735 GB9501735W WO9603142A1 WO 1996003142 A1 WO1996003142 A1 WO 1996003142A1 GB 9501735 W GB9501735 W GB 9501735W WO 9603142 A1 WO9603142 A1 WO 9603142A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- delivery composition
- icam
- microspheres
- chitosan
- composition according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU29886/95A AU707462C (en) | 1994-07-26 | 1995-07-24 | Drug delivery composition for the nasal administration of antiviral agents |
EP95925947A EP0773791A1 (en) | 1994-07-26 | 1995-07-24 | Drug delivery composition for the nasal administration of antiviral agents |
GB9700817A GB2305606B (en) | 1994-07-26 | 1995-07-24 | Drug delivery composition for the nasal administration of ICAM-1 |
JP8505576A JPH10506376A (en) | 1994-07-26 | 1995-07-24 | Drug delivery composition and drug administration method |
NO970252A NO970252L (en) | 1994-07-26 | 1997-01-21 | Mixture for nasal administration of a drug |
FI970331A FI970331A (en) | 1994-07-26 | 1997-01-27 | Drug composition for nasal administration of antiviral agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9414966.3 | 1994-07-26 | ||
GB9414966A GB9414966D0 (en) | 1994-07-26 | 1994-07-26 | Pharmaceutical compositions for the nasal administration of antiviral agents |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08776470 A-371-Of-International | 1997-03-28 | ||
US09/848,600 Continuation US20010053359A1 (en) | 1994-07-26 | 2001-05-03 | Drug delivery composition for the nasal administration of antiviral agents |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996003142A1 true WO1996003142A1 (en) | 1996-02-08 |
Family
ID=10758832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1995/001735 WO1996003142A1 (en) | 1994-07-26 | 1995-07-24 | Drug delivery composition for the nasal administration of antiviral agents |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0773791A1 (en) |
JP (1) | JPH10506376A (en) |
CA (1) | CA2195639A1 (en) |
FI (1) | FI970331A (en) |
GB (2) | GB9414966D0 (en) |
NO (1) | NO970252L (en) |
WO (1) | WO1996003142A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997032596A1 (en) * | 1996-03-06 | 1997-09-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Intercellular adhesion molecule powder formulation |
EP0833614A1 (en) * | 1995-06-07 | 1998-04-08 | Sri International | System and method for producing drug-loaded microparticles |
WO1998030207A1 (en) * | 1997-01-14 | 1998-07-16 | Danbiosyst Uk Limited | Chitosan-gelatin a microparticles |
WO1999022768A1 (en) * | 1997-10-31 | 1999-05-14 | Monsanto Company | Controlled release compositions comprising gellan gum gels |
EP0994700A1 (en) * | 1997-07-18 | 2000-04-26 | Bayer Corporation | Methods of removing residual solvent from nasal drug delivery compositions |
JP2001524509A (en) * | 1997-12-02 | 2001-12-04 | ウエスト・ファーマシューティカル・サービセズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド | Composition for nasal administration |
WO2002000268A1 (en) * | 2000-06-28 | 2002-01-03 | Bristol-Myers Squibb Company | Sprayable wound care compositions |
US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
GB2378383A (en) * | 2001-06-06 | 2003-02-12 | Gursharan Moonga | Nasal delivery of pharmaceutical compositions in powder form |
WO2005079749A3 (en) * | 2004-02-21 | 2006-03-23 | Cal Res Ct Ltd West Pharmaceut | Chitosan containing solution |
WO2008091588A1 (en) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
JP2009079052A (en) * | 1997-04-18 | 2009-04-16 | Archimedes Development Ltd | Improved delivery of drug to mucosal surface |
DE102008007759A1 (en) | 2007-12-04 | 2009-06-18 | Atlantichem Gmbh | Agent, useful for avoiding discoloration and graying during the washing of textiles, comprises a cationized substrate in the form of e.g. cationized cord thread sections and detergent-active and/or textile-maintaining ingredients |
US7947257B2 (en) | 2003-12-05 | 2011-05-24 | Archimedes Development Limited | Method of intranasal administration of granisetron |
US8216604B2 (en) | 2003-01-10 | 2012-07-10 | Archimedes Development Limited | Method of managing or treating pain |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0314863A2 (en) * | 1987-11-02 | 1989-05-10 | Baylor College Of Medicine | Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation |
EP0362531A1 (en) * | 1988-09-01 | 1990-04-11 | Bayer Corporation | A human rhinovirus receptor protein that inhibits virus infectivity |
WO1990005522A1 (en) * | 1988-11-17 | 1990-05-31 | Per Prisell | Pharmaceutical preparation |
WO1991006282A1 (en) * | 1989-11-04 | 1991-05-16 | Danbiosyst Uk Limited | Small particle drug compositions |
WO1993006842A1 (en) * | 1991-10-02 | 1993-04-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma |
WO1994000485A1 (en) * | 1992-06-22 | 1994-01-06 | Miles Inc. | Multimeric forms of human rhinovirus receptor protein |
WO1994027576A1 (en) * | 1993-05-20 | 1994-12-08 | Danbiosyst Uk Limited | Nasal drug delivery composition containing nicotine |
-
1994
- 1994-07-26 GB GB9414966A patent/GB9414966D0/en active Pending
-
1995
- 1995-07-24 CA CA002195639A patent/CA2195639A1/en not_active Abandoned
- 1995-07-24 WO PCT/GB1995/001735 patent/WO1996003142A1/en not_active Application Discontinuation
- 1995-07-24 EP EP95925947A patent/EP0773791A1/en not_active Withdrawn
- 1995-07-24 JP JP8505576A patent/JPH10506376A/en active Pending
- 1995-07-24 GB GB9700817A patent/GB2305606B/en not_active Expired - Fee Related
-
1997
- 1997-01-21 NO NO970252A patent/NO970252L/en not_active Application Discontinuation
- 1997-01-27 FI FI970331A patent/FI970331A/en not_active IP Right Cessation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0314863A2 (en) * | 1987-11-02 | 1989-05-10 | Baylor College Of Medicine | Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation |
EP0362531A1 (en) * | 1988-09-01 | 1990-04-11 | Bayer Corporation | A human rhinovirus receptor protein that inhibits virus infectivity |
WO1990005522A1 (en) * | 1988-11-17 | 1990-05-31 | Per Prisell | Pharmaceutical preparation |
WO1991006282A1 (en) * | 1989-11-04 | 1991-05-16 | Danbiosyst Uk Limited | Small particle drug compositions |
WO1993006842A1 (en) * | 1991-10-02 | 1993-04-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma |
WO1994000485A1 (en) * | 1992-06-22 | 1994-01-06 | Miles Inc. | Multimeric forms of human rhinovirus receptor protein |
WO1994027576A1 (en) * | 1993-05-20 | 1994-12-08 | Danbiosyst Uk Limited | Nasal drug delivery composition containing nicotine |
Non-Patent Citations (2)
Title |
---|
L. ILLUM: "The nasal delivery of peptides and proteins.", TRENDS IN BIOTECHNOLOGY, vol. 9, no. 8, CAMBRIDGE, GB, pages 284 - 289 * |
S MARLIN ET AL.: "A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection.", NATURE, vol. 344, 1 March 1990 (1990-03-01), LONDON, GB, pages 70 - 72 * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0833614A1 (en) * | 1995-06-07 | 1998-04-08 | Sri International | System and method for producing drug-loaded microparticles |
US7087245B2 (en) | 1995-06-07 | 2006-08-08 | Bomberger David C | ICAM-1 formulation having controlled-size microparticles |
EP0833614A4 (en) * | 1995-06-07 | 2001-07-11 | Stanford Res Inst Int | System and method for producing drug-loaded microparticles |
WO1997032596A1 (en) * | 1996-03-06 | 1997-09-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Intercellular adhesion molecule powder formulation |
US6465626B1 (en) | 1997-01-14 | 2002-10-15 | West Pharmaceutical Services Drug Delivery And Clincal Research Centre, Limited | Pharmaceutical compositions of chitosan with type-A gelatin |
WO1998030207A1 (en) * | 1997-01-14 | 1998-07-16 | Danbiosyst Uk Limited | Chitosan-gelatin a microparticles |
GB2335357A (en) * | 1997-01-14 | 1999-09-22 | Danbiosyst Uk | Chitosan-gelatin A microparticles |
GB2335357B (en) * | 1997-01-14 | 2000-12-13 | Danbiosyst Uk Ltd | Chitosan-gelatin a microparticles |
JP2009079052A (en) * | 1997-04-18 | 2009-04-16 | Archimedes Development Ltd | Improved delivery of drug to mucosal surface |
EP0994700A4 (en) * | 1997-07-18 | 2000-10-18 | Bayer Ag | Methods of removing residual solvent from nasal drug delivery compositions |
US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
EP0994700A1 (en) * | 1997-07-18 | 2000-04-26 | Bayer Corporation | Methods of removing residual solvent from nasal drug delivery compositions |
WO1999022768A1 (en) * | 1997-10-31 | 1999-05-14 | Monsanto Company | Controlled release compositions comprising gellan gum gels |
AU744328B2 (en) * | 1997-10-31 | 2002-02-21 | Cp Kelco Aps | Controlled release compositions comprising gellan gum gels |
JP2001524509A (en) * | 1997-12-02 | 2001-12-04 | ウエスト・ファーマシューティカル・サービセズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド | Composition for nasal administration |
JP4754067B2 (en) * | 1997-12-02 | 2011-08-24 | アルキメデス ディヴェロプメント リミテッド | Composition for nasal administration |
WO2002000268A1 (en) * | 2000-06-28 | 2002-01-03 | Bristol-Myers Squibb Company | Sprayable wound care compositions |
GB2378383A (en) * | 2001-06-06 | 2003-02-12 | Gursharan Moonga | Nasal delivery of pharmaceutical compositions in powder form |
US8216604B2 (en) | 2003-01-10 | 2012-07-10 | Archimedes Development Limited | Method of managing or treating pain |
US8889176B2 (en) | 2003-01-10 | 2014-11-18 | Depomed, Inc. | Method of managing or treating pain |
US9078814B2 (en) | 2003-01-10 | 2015-07-14 | Depomed, Inc. | Intranasal spray device containing pharmaceutical composition |
US9814705B2 (en) | 2003-01-10 | 2017-11-14 | Depomed, Inc. | Intranasal spray device containing pharmaceutical composition |
US7947257B2 (en) | 2003-12-05 | 2011-05-24 | Archimedes Development Limited | Method of intranasal administration of granisetron |
WO2005079749A3 (en) * | 2004-02-21 | 2006-03-23 | Cal Res Ct Ltd West Pharmaceut | Chitosan containing solution |
WO2008091588A1 (en) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
DE102008007759A1 (en) | 2007-12-04 | 2009-06-18 | Atlantichem Gmbh | Agent, useful for avoiding discoloration and graying during the washing of textiles, comprises a cationized substrate in the form of e.g. cationized cord thread sections and detergent-active and/or textile-maintaining ingredients |
Also Published As
Publication number | Publication date |
---|---|
GB9414966D0 (en) | 1994-09-14 |
FI970331A0 (en) | 1997-01-27 |
CA2195639A1 (en) | 1996-02-08 |
NO970252D0 (en) | 1997-01-21 |
AU2988695A (en) | 1996-02-22 |
NO970252L (en) | 1997-01-21 |
JPH10506376A (en) | 1998-06-23 |
GB2305606A (en) | 1997-04-16 |
EP0773791A1 (en) | 1997-05-21 |
GB9700817D0 (en) | 1997-03-05 |
AU707462B2 (en) | 1999-07-08 |
GB2305606B (en) | 1998-08-05 |
FI970331A (en) | 1997-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20010053359A1 (en) | Drug delivery composition for the nasal administration of antiviral agents | |
Barclay et al. | Review of polysaccharide particle-based functional drug delivery | |
EP0697858B1 (en) | Nasal drug delivery composition containing nicotine | |
WO1996003142A1 (en) | Drug delivery composition for the nasal administration of antiviral agents | |
Gåserød et al. | The enhancement of the bioadhesive properties of calcium alginate gel beads by coating with chitosan | |
Rassu et al. | Composite chitosan/alginate hydrogel for controlled release of deferoxamine: A system to potentially treat iron dysregulation diseases | |
Coviello et al. | Polysaccharide hydrogels for modified release formulations | |
Harding et al. | Biopolymer mucoadhesives | |
US6207197B1 (en) | Gastroretentive controlled release microspheres for improved drug delivery | |
Kas | Chitosan: properties, preparations and application to microparticulate systems | |
JPH04503508A (en) | drug delivery composition | |
JP2009537597A (en) | Polymer mixtures of anionic and cationic polysaccharides and their use | |
JP2009511549A (en) | Chitosan and heparin nanoparticles | |
Valente et al. | Polysaccharide-based formulations as potential carriers for pulmonary delivery–a review of their properties and fates | |
AU6219599A (en) | Formulations of fexofenadine | |
JP2003525980A (en) | Clathrate complexes formed by hyaluronic acid derivatives and their use as pharmaceuticals | |
Shariatinia | Biopolymeric nanocomposites in drug delivery | |
Khvostov et al. | Application of natural polysaccharides in pharmaceutics | |
CN117100691A (en) | Enhancement of mucus barrier performance | |
AU707462C (en) | Drug delivery composition for the nasal administration of antiviral agents | |
Pelin et al. | Mucoadhesive buccal drug delivery systems containing polysaccharides | |
Patil et al. | Crosslinking of polysaccharides: methods and applications | |
Khandelwal et al. | Polysaccharides and Natural Gums for Colon Drug Delivery. | |
EP1011722B1 (en) | Substrates materials with bound cytokine-stimulating polysaccharides or bacterial nucleic acids | |
JP2010090314A (en) | Insoluble cationic polysaccharide film |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995925947 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2195639 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 970331 Country of ref document: FI |
|
ENP | Entry into the national phase |
Ref document number: 1997 776470 Country of ref document: US Date of ref document: 19970328 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1995925947 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995925947 Country of ref document: EP |